Marevan (Warfarin Sodium)

Warfarin sodium blocks the enzyme vitamin K epoxide reductase, which is needed to recycle vitamin K. Without active vitamin K, the liver produces lower amounts of clotting factors II, VII, IX, and X, resulting in reduced blood coagulation and a lower likelihood of clot formation.

The dose of Marevan is individualized. A qualified prescriber determines the appropriate amount based on the patient’s medical condition, INR monitoring results, and other clinical factors. Patients should follow the prescribing clinician’s instructions and attend regular blood‑test appointments.

Marevan (warfarin sodium) is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to the risk of fetal bleeding and malformations. It is also not recommended while breastfeeding because it can pass into breast milk and affect the infant.

To order Marevan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Marevan (warfarin) is a long‑standing oral vitamin K antagonist, whereas newer agents such as direct oral anticoagulants (DOACs) target specific clotting factors and often require less monitoring. Warfarin offers a reversible effect with vitamin K and has a well‑known interaction profile, making it suitable for patients needing tight control or those with certain renal impairments.

Marevan should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Marevan is taken orally, usually once daily, with or without food as directed by the prescriber. The exact timing and whether it should be taken at the same time each day are determined by the treating clinician based on INR monitoring.

The most serious risks include severe or uncontrolled bleeding, hemorrhagic stroke, and skin necrosis. Patients should immediately report any unusual bruising, blood in urine or stool, severe headache, or signs of allergic reaction to their healthcare provider.

Marevan should not be used by individuals who are pregnant, have uncontrolled hypertension, active major bleeding, recent major surgery, or known hypersensitivity to warfarin. It is also contraindicated in patients with severe liver disease or those taking certain interacting medications without close monitoring.